I-Mab (IMAB)

NASDAQ: IMAB · Real-Time Price · USD
0.980
+0.057 (6.28%)
Dec 23, 2024, 11:18 AM EST - Market open
6.28%
Market Cap 79.84M
Revenue (ttm) 3.31M
Net Income (ttm) -82.29M
Shares Out 81.50M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 57,738
Open 0.940
Previous Close 0.923
Day's Range 0.936 - 0.990
52-Week Range 0.899 - 2.536
Beta 1.04
Analysts Strong Buy
Price Target 8.00 (+716.66%)
Earnings Date Aug 28, 2024

About IMAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 17, 2020
Employees 220
Stock Exchange NASDAQ
Ticker Symbol IMAB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for IMAB stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 716.66% from the latest price.

Price Target
$8.0
(716.66% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

I-Mab to Participate at the Piper Sandler Healthcare Conference

The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024 ROCKVILLE, Md. , Nov. 21, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB, the "Company"), a U.S.-based global biotech compa...

4 weeks ago - PRNewsWire

I-Mab Reports Third Quarter 2024 Results

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 A...

5 weeks ago - PRNewsWire

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

ROCKVILLE, Md. , Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies...

6 weeks ago - PRNewsWire

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

ROCKVILLE, Md. , Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies...

7 weeks ago - PRNewsWire

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

-  Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024 ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASD...

7 weeks ago - PRNewsWire

I-Mab to Participate at the Truist Securities BioPharma Symposium

ROCKVILLE, Md. , Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatm...

2 months ago - PRNewsWire

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers...

3 months ago - PRNewsWire

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials - Exposure-Response (E-R) Analysis showed a positive correlatio...

3 months ago - PRNewsWire

I-MAB (IMAB) Q2 2024 Earnings Call Transcript

I-MAB Biopharma (NASDAQ:IMAB) Q2 2024 Earnings Conference Call August 28, 2024 8:00 AM ET Company Participants Sean Fu - Chief Executive Officer (interim) Phillip Dennis - Chief Medical Officer Josep...

4 months ago - Seeking Alpha

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

Completed divestiture of China operations Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody) Clinical collaboration and supply agreement with Bri...

4 months ago - PRNewsWire

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

ROCKVILLE, Md. , Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies...

4 months ago - PRNewsWire

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB...

4 months ago - PRNewsWire

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKVILLE, Md. , Aug. 7, 2024 /PRNewswire/ -- I...

4 months ago - PRNewsWire

I-Mab Announces Leadership Transitions

ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has app...

5 months ago - PRNewsWire

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastri...

Other symbols: BMY
7 months ago - PRNewsWire

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hi...

7 months ago - GlobeNewsWire

I-Mab to Participate at the Jefferies Global Healthcare Conference

ROCKVILLE, Md. , May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated...

7 months ago - PRNewsWire

I-MAB Filed 2023 Annual Report on Form 20-F

ROCKVILLE, Md. , April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hi...

8 months ago - PRNewsWire

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md. , April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiat...

9 months ago - PRNewsWire

I-Mab Announces Closing of the Divestiture of Business Operations in China

ROCKVILLE, Md. , April 2, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of high...

9 months ago - PRNewsWire

I-Mab Reports Full Year 2023 Financial Results and Business Update

Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 Uliledlimab (...

10 months ago - PRNewsWire

I-Mab: Trading Below Net Cash With Multiple Upside Options

I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over ...

11 months ago - Seeking Alpha

Biotech firm I-Mab to divest China operations, shift focus to US

I-Mab said on Wednesday it has agreed to divest its operations and assets in China as part of its strategy to become a U.S.-focused biotech firm, sending the company's shares up nearly 11% in premarke...

11 months ago - Reuters

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech  Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncolog...

11 months ago - PRNewsWire

I-Mab Announces Participation at Jefferies and Piper Conferences in November

ROCKVILLE, Md. and SHANGHAI, China , Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients a...

1 year ago - PRNewsWire